Knockdown of ELMO3 Suppresses Growth, Invasion and Metastasis of Colorectal Cancer

Peng, Huiyun; Yu, Qianli; Shen, Wei Feng; Guo, Cheng-Ming; Li, Zhen; Zhou, Xiaoyan; Zhou, Nan; Min, Wei‐Ping; Gao, Dian

doi:10.3390/ijms17122119

Cited by 15 publications

(20 citation statements)

References 44 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings further support our hypothesis that ELMO3 is involved in the process of GC cell growth. This is also in agreement with our previous report on colorectal cancer, in which silencing ELMO3 significantly induced G1 cell cycle arrest [ 23 ]. ELMO3 inhibition could be a promising option for slowing or preventing the progression of GC.…”

Section: Discussionsupporting

confidence: 93%

“…In addition, RNA interference treatment was employed to inhibit the expression of ELMO3 in GC SGC7901 and BGC823 cells in the following experiments. An ELMO3-specific siRNA (siELMO3) sequence was used as previously described [ 23 ], and it resulted in approximately 75% knockdown efficiency in the two cell lines (data not shown).…”

Section: Resultsmentioning

confidence: 99%

“…Then, 2 µ g of total RNA as a template was used to generate cDNA with a cDNA synthesis kit (Promega Corporation, Madison, WI, USA). The real-time reverse transcription-polymerase chain (qPCR) reaction was carried out with specific primers as per the protocol described in our previous report [ 23 ].…”

Section: Methodsmentioning

confidence: 99%

“…To determine the protein level of ELMO3, Western blot analysis was conducted as previously described [ 23 , 27 ]. Briefly, 35 μ g of total protein was resolved by 12% SDS-PAGE gel electrophoresis followed by transfer onto PVDF membranes.…”

Section: Methodsmentioning

confidence: 99%

“…Compared with ELMO1 and ELMO2, the biological functions of ELMO3 remain largely unknown. The expression of ELMO3 has been reported in lung cancer [ 19 – 22 ], colorectal cancer [ 23 ], head and neck squamous cell carcinomas [ 24 ], and laryngeal cancer [ 25 ], etc. In these cancers, upregulation of ELMO3 is commonly involved in tumor development and metastasis formation.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Silencing ELMO3 Inhibits the Growth, Invasion, and Metastasis of Gastric Cancer

Zhong

et al. 2018

BioMed Research International

Self Cite

View full text Add to dashboard Cite

ELMO3 is a member of the engulfment and cell motility (ELMO) protein family, which plays a vital role in the process of chemotaxis and metastasis of tumor cells. However, remarkably little is known about the role of ELMO3 in cancer. The present study was conducted to investigate the function and role of ELMO3 in gastric cancer (GC) progression. The expression level of ELMO3 in gastric cancer tissues and cell lines was measured by means of real-time quantitative PCR (qPCR) and Western blot analysis. RNA interference was used to inhibit ELMO3 expression in gastric cancer cells. Then, wound-healing assays, Transwell assays, MTS assays, flow cytometry, and fluorescence microscopy were applied to detect cancer cell migration, cell invasion, cell proliferation, the cell cycle, and F-actin polymerization, respectively. The results revealed that ELMO3 expression in GC tumor tissues was significantly higher than in the paired adjacent tissues. Moreover, knockdown of ELMO3 by a specific siRNA significantly inhibited the processes of cell proliferation, invasion, metastasis, regulation of the cell cycle, and F-actin polymerization. Collectively, the results indicate that ELMO3 participates in the processes of cell growth, invasion, and migration, and ELMO3 is expected to be a potential diagnostic and prognostic marker for GC.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Silencing ELMO3 Inhibits the Growth, Invasion, and Metastasis of Gastric Cancer

Zhong

et al. 2018

BioMed Research International

Self Cite

View full text Add to dashboard Cite

show abstract

Prediction of distant metastasis and specific survival prediction of small intestine cancer patients with metastasis: A population‐based study

Yao

Liao³

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

BackgroundSmall intestine cancer (SIC) is difficult to diagnose early and presents a poor prognosis due to distant metastasis. This study aimed to develop nomograms for diagnosing and assessing the prognosis of SIC with distant metastasis.MethodsPatients diagnosed with SIC between 2010 and 2015 were included from the Surveillance, Epidemiology and End Results database. Univariate and multifactor analysis determined independent risk factors for distant metastasis and prognostic factors for overall and cancer‐specific survival. We then constructed the corresponding three nomograms and assessed the diagnostic accuracy of the nomograms by net reclassification improvement, receiver operating characteristic curves and calibration curves, assessed the clinical utility by decision curve analysis.RESULTSThe cohort consisted of 6697 patients, of whom 1299 had distant metastasis at diagnosis. Tstage, Nstage, age, tumor size, grade, and histological type were independent risk factors for distant metastasis. Age, histological type, T stage, N stage, grade, tumor size, whether receiving surgery, number of lymph nodes removed, and the presence of bone or lung metastases were predictors of both overall survival and cancer‐specific survival. The nomograms showed excellent accuracy in predicting distant metastasis and prognosis.ConclusionNomograms were developed and validated for SIC patients with distant metastasis, aiding physicians in making rational and personalized clinical decisions.

show abstract

Metformin ameliorates the severity of experimental Alport syndrome

Omachi

Kaseda

Yokota

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Metformin is widely used for the treatment of type 2 diabetes, and increasing numbers of studies have shown that metformin also ameliorates tumor progression, inflammatory disease, and fibrosis. However, the ability of metformin to improve non-diabetic glomerular disease and chronic kidney disease (CKD) has not been explored. To investigate the effect of metformin on non-diabetic glomerular disease, we used a mouse model of Alport syndrome (Col4a5 G5X) which were treated with metformin or losartan, used as a control treatment. We also investigated the effect of metformin on adriamycin-induced glomerulosclerosis model. Pathological and biochemical analysis showed that metformin or losartan suppressed proteinuria, renal inflammation, fibrosis, and glomerular injury and extended the lifespan in Alport syndrome mice. Transcriptome analysis showed that metformin and losartan influenced molecular pathways-related to metabolism and inflammation. Metformin altered multiple genes including metabolic genes not affected by losartan. Metformin also suppressed proteinuria and glomerular injury in the adriamycin-induced glomerulosclerosis mouse model. Our results showed that metformin ameliorates the glomerular sclerosis and CKD phenotype in non-diabetic chronic glomerular diseases. Metformin may have therapeutic potential for not only diabetic nephropathy but also non-diabetic glomerular disease including Alport syndrome.

show abstract

Knockdown of ELMO3 Suppresses Growth, Invasion and Metastasis of Colorectal Cancer

Cited by 15 publications

References 44 publications

Silencing ELMO3 Inhibits the Growth, Invasion, and Metastasis of Gastric Cancer

Silencing ELMO3 Inhibits the Growth, Invasion, and Metastasis of Gastric Cancer

Prediction of distant metastasis and specific survival prediction of small intestine cancer patients with metastasis: A population‐based study

Metformin ameliorates the severity of experimental Alport syndrome

Contact Info

Product

Resources

About